摘要:
This invention provides a composition for heart disease comprising extracts from raw herbs of 80.0-97.0% Radix Salviae Miltorrhizae, 1.0-19.0% Panax Notoginseng and 0.1-1.0% Borneol and its active ingredients. This invention also provides a method for preparing said composition and the active ingredients of the composition. Finally, this invention provides various uses of said compositions and the active ingredients.
摘要:
This invention provides a composition for heart disease comprising extracts from raw herbs of 80.0-97.0% Radix Salviae Miltorrhizae, 1.0-19.0% Panax Notoginseng and 0.1-1.0% Borneol and its active ingredients. This invention also provides a method for preparing said composition and the active ingredients of the composition. Finally, this invention provides various uses of said compositions and the active ingredients.
摘要:
This invention provides compositions comprising extracts of Radix Salviae Miltiorrhizae, Radix Notoginseng and Borneol. Said compositions comprise notoginsenoside R1 and ginsenoside Rg1 which are active components for therapeutic applications. This invention also provides a method of preparation of the said compositions and a method of identification and determination of the amount of individual effective components of said compositions. Finally, this invention provides various uses of the compositions.
摘要:
The present invention relates to the treatment of aspirin resistant cardio-cerebrovascular diseases using RSM (RSM), its extract and composition comprising any or both of them, especially the formulation Dan Shen Drop Pills (Drop Pills of RSM).
摘要:
Provided is the use of a Salvia Miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease, and particularly the use of the Salvia Miltiorrhiza composition in preparing drugs for secondary prevention of stable angina type coronary heart disease and the reduction of serious vascular events.
摘要:
Provided is the use of a Salvia Miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease, and particularly the use of the Salvia Miltiorrhiza composition in preparing drugs for secondary prevention of stable angina type coronary heart disease and the reduction of serious vascular events.